Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.

IF 2.5 Q3 ONCOLOGY Journal of Cancer Prevention Pub Date : 2021-12-30 DOI:10.15430/JCP.2021.26.4.309

Altaf Mohammed, Roderick H Dashwood, Sally Dickinson, Mary L Disis, Elizabeth M Jaffee, Bryon D Johnson, Samir N Khleif, Michael N Pollak, Jeffrey Schlom, Robert H Shoemaker, Sasha E Stanton, Georg T Wondrak, Ming You, Hao Zhu, Mark Steven Miller

{"title":"Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report.","authors":"Altaf Mohammed, Roderick H Dashwood, Sally Dickinson, Mary L Disis, Elizabeth M Jaffee, Bryon D Johnson, Samir N Khleif, Michael N Pollak, Jeffrey Schlom, Robert H Shoemaker, Sasha E Stanton, Georg T Wondrak, Ming You, Hao Zhu, Mark Steven Miller","doi":"10.15430/JCP.2021.26.4.309","DOIUrl":null,"url":null,"abstract":"<p><p>The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) convened the \"Translational Advances in Cancer Prevention Agent Development (TACPAD) Workshop on Immunomodulatory Agents\" as a virtual 2-day workshop on September 13 to 14, 2021. The main goals of this workshop were to foster the exchange of ideas and potentially new collaborative interactions among leading cancer immunoprevention researchers from basic and clinical research and highlight new and emerging trends in immunoprevention. The workshop included an overview of the mechanistic classes of immunomodulatory agents and three sessions covering the gamut from preclinical to clinical studies. The workshop convened individuals working in immunology and cancer prevention to discuss trends in discovery and development of immunomodulatory agents individually and in combination with other chemopreventive agents or vaccines.</p>","PeriodicalId":15120,"journal":{"name":"Journal of Cancer Prevention","volume":"26 4","pages":"309-317"},"PeriodicalIF":2.5000,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2a/f9/jcp-26-4-309.PMC8749317.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15430/JCP.2021.26.4.309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

The National Cancer Institute (NCI) Division of Cancer Prevention (DCP) convened the "Translational Advances in Cancer Prevention Agent Development (TACPAD) Workshop on Immunomodulatory Agents" as a virtual 2-day workshop on September 13 to 14, 2021. The main goals of this workshop were to foster the exchange of ideas and potentially new collaborative interactions among leading cancer immunoprevention researchers from basic and clinical research and highlight new and emerging trends in immunoprevention. The workshop included an overview of the mechanistic classes of immunomodulatory agents and three sessions covering the gamut from preclinical to clinical studies. The workshop convened individuals working in immunology and cancer prevention to discuss trends in discovery and development of immunomodulatory agents individually and in combination with other chemopreventive agents or vaccines.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症预防剂开发的转化进展(TACPAD)免疫调节剂虚拟研讨会:报告。

美国国家癌症研究所(NCI)癌症预防部(DCP)于2021年9月13日至14日召开了为期2天的虚拟研讨会“癌症预防剂开发的转化进展(TACPAD)免疫调节剂研讨会”。本次研讨会的主要目标是促进来自基础和临床研究的领先癌症免疫预防研究人员之间的思想交流和潜在的新的合作互动，并强调免疫预防的新趋势。研讨会包括免疫调节剂的机制类别概述和三个会议，涵盖从临床前到临床研究的范围。讲习班召集了从事免疫学和癌症预防工作的个人，讨论单独或与其他化学预防剂或疫苗联合发现和开发免疫调节剂的趋势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cancer Prevention ONCOLOGY-

自引率

4.00%

发文量